00:00 Elysio Therapeutics Inc., trading on the Nasdaq under ELTX, is a company founded in 2011 working
00:08 on advanced cancer treatments using vaccines and therapies that trigger the body's immune
00:12 system to fight cancer.
00:13 They have three main vaccine candidates, ELI-002, ELI-007, and ELI-008.
00:21 ELI-002 targets a specific mutation, KRAS, found in 25% of solid tumors.
00:28 It stimulates the immune system to attack cancer cells.
00:31 The vaccine is designed to cover seven common KRAS mutations.
00:36 ELI-007 is a vaccine for cancers with BRAF V600E mutations present in melanoma, colon,
00:44 and lung cancers.
00:45 It aims to sustain immune responses, addressing resistance issues seen with current treatments.
00:50 ELI-008 targets mutations in P53 found in many cancers.
00:55 The vaccine enhances immune response in draining lymph nodes to eliminate tumor tissue.
01:00 Elysio Therapeutics is conducting trials to ensure these treatments are effective and
01:03 can reach a broader range of patients.
01:06 Their approach involves precise targeting of lymph nodes, crucial in orchestrating the
01:09 immune response against cancer.
01:11 Overall, they are at the forefront of cancer treatment through vaccination, combining expertise
01:16 in immunology and immunotherapy.
01:18 [MUSIC PLAYING]
Comments